# A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients

Study · id `cardio:ct-nct04197479` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04197479](<https://clinicaltrials.gov/study/NCT04197479>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04197479

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1343 participants.

## Technical summary

Registry record NCT04197479. Randomized; quadruple masking; primary purpose treatment. Start 2019-12-16 (actual); primary completion 2023-01-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1343 participants (enrolled count; ClinicalTrials.gov record NCT04197479, source copy `cardio:ctgov-nct04197479-2023-09-05`, retrieved 2026-10-31)
- Started: 2019-12-16 (actual) (ClinicalTrials.gov record NCT04197479, source copy `cardio:ctgov-nct04197479-2023-09-05`, retrieved 2026-10-31)
- Primary completion: 2023-01-06 (actual) (ClinicalTrials.gov record NCT04197479, source copy `cardio:ctgov-nct04197479-2023-09-05`, retrieved 2026-10-31)
- Completion: 2023-01-06 (actual) (ClinicalTrials.gov record NCT04197479, source copy `cardio:ctgov-nct04197479-2023-09-05`, retrieved 2026-10-31)
- Countries: United States; Puerto Rico (ClinicalTrials.gov record NCT04197479, source copy `cardio:ctgov-nct04197479-2023-09-05`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04197479-2023-09-05`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
- Acronym: MAESTRO-NAFLD1
- Condition: Non-Alcoholic Fatty Liver Disease
- Intervention (Drug): Placebo
- Intervention (Drug): Resmetirom
- Lead sponsor: Madrigal Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial (`cardio:pubmed-37845512`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 87da3871c58dd446a25b27a29321881aedaa9cfbdaac2e77bd1d5dff57288f4a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
